[(1-溴乙烯基)硫基]苯 | 80485-53-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: [(1-溴乙烯基)硫基]苯
• 英文名称: phenyl α-bromovinyl sulfide
• 英文别名: 1-bromo-1-(phenylthio)ethene；1-bromo-1-phenylthioethene；[(1-Bromoethenyl)sulfanyl]benzene；1-bromoethenylsulfanylbenzene
• CAS: 80485-53-6
• 化学式: C₈H₇BrS
• 分子量: 215.114
• InChiKey: LKASAGHKSNNTMN-UHFFFAOYSA-N

物化性质

• 沸点：
  263℃
• 密度：
  1.47
• 闪点：
  113℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [(1-溴乙烯基)硫基]苯 在 正丁基锂 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 苯 为溶剂， 反应 27.0h， 生成 2-acetyl-2,5-bis(phenylthio)-6-methyl-3,4-dihydropyran
  参考文献：
  名称：

  Reactions of 3-(phenylthio)-3-buten-2-one with cycloalkanones. A new approach to fused phenols

  摘要：

  DOI：

  10.1021/jo00346a012
• 作为产物：
  描述：

  α-Bromoethyl phenyl sulfoxide 在 三氟甲磺酸三甲基硅酯 、 三乙胺 作用下， 以 乙醚 为溶剂， 反应 0.5h， 以77%的产率得到[(1-溴乙烯基)硫基]苯
  参考文献：
  名称：

  Moller, R. D.; Haessig, R., Synthetic Communications, 1984, vol. 14, # 14, p. 1285 - 1290

  摘要：

  DOI：

文献信息

• Acetal−Vinyl Sulfide Cyclization on Sugar Substrates:  Effect of Structure and Substituent
  作者：Pradip K. Sasmal、Martin E. Maier

  DOI：10.1021/jo026163i

  日期：2003.2.1

  vinyl or propenyl side chain. Extension of the alkene by a Suzuki cross-coupling reaction with 1-bromo-1-(phenylthio)ethene gave thioenol ethers as the cyclization substrates. The treatment of these substrates with BF(3).Et(2)O in tert-butylmethyl ether below 0 degrees C induced cyclization to optically active bicyclic ethers. If the cyclizations are carried out in toluene as the solvent, the isomerization

  一系列2-脱氧呋喃糖苷和-吡喃糖苷衍生物被制成带有乙烯基或丙烯基侧链的衍生物。通过与1-溴-1-（苯硫基）乙烯的铃木（Suzuki）交叉偶联反应进行烯烃的延伸，得到硫代烯醇醚作为环化底物。在低于0摄氏度的叔丁基甲基醚中用BF（3）.Et（2）O处理这些底物可诱导环化为光学活性双环醚。如果环化是在甲苯作为溶剂中进行的，则末端硫烯醇醚异构化为内部的硫烯醇醚可以在环化之前进行。空间和电子因素可能会阻碍环化反应。双环醚的开放可以用酮53向环辛烯酮54的碱诱导转化来说明。
• Formation of Bicyclic Ethers from Lewis Acid Promoted Cyclizations of Cyclic Oxonium Ions
  作者：Pradip K. Sasmal、Martin E. Maier

  DOI：10.1021/ol025570d

  日期：2002.4.1

  Oxacycles carrying a vinyl group and an acetal were extended with a cyclization terminator (vinyl silane or vinyl sulfide) by Suzuki coupling. Treatment with Lewis acid induced cyclization to provide bicyclic ethers in reasonable yields. In the case of the vinyl silane, an ene-like mechanism is preferred, whereas the thioenol ether enters into a Prins-type reaction channel. In one instance, the bicyclic

  通过铃木偶合，用环化终止剂（乙烯基硅烷或乙烯基硫化物）使带有乙烯基和乙缩醛的氧环延长。用路易斯酸处理诱导环化，以合理的产率提供双环醚。在乙烯基硅烷的情况下，优选烯类机理，而硫烯醇醚进入Prins型反应通道。在一种情况下，将双环化合物打开以得到十元官能化的烯酮24。
• Stereoselective Syntheses of Conjugated 1-Phenylthio-1,3-alkadienes and 1,3,5-Alkatrienes through the Palladium-Catalyzed Cross-Coupling Reaction of (<i>E</i>)- or (<i>Z</i>)-1-Alkenylboronates with (<i>E</i>)- or (<i>Z</i>)-2-Bromo-1-phenylthio-1-alkenes
  作者：Tatsuo Ishiyama、Norio Miyaura、Akira Suzuki

  DOI：10.1246/cl.1987.25

  日期：1987.1.5

  1-Phenylthio-1,3-alkadienes and 1,3,5-alkatrienes are obtained in excellent yields stereo- and regioselectively by the cross-coupling between 1-alkenyl or 1,3-alkadienyl-1,3,2-benzodioxaboroles and (E)- or (Z)-2-bromo-1-phenylthio-1-alkenes in the presence of a catalytic amount of Pd(PPh3)4. These sulfides are converted to the corresponding conjugated alkatrienes and tetraenes by the reaction with Grignard

  通过 1-链烯基或 1,3-链二烯基-1,3,2-苯并二氧杂环戊烷和(E)- 或 (Z)-2-bromo-1-phenylthio-1- 烯烃在催化量的 Pd(PPh3)4 存在下。这些硫化物在镍催化剂存在下通过与格氏试剂反应转化为相应的共轭烷三烯和四烯。
• Resolvins: biotemplates for novel therapeutic interventions
  申请人：——

  公开号：US20040116408A1

  公开（公告）日：2004-06-17

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

  本发明一般涉及新型分离治疗剂，称为 "溶解"，由膳食中的ω-3 多不饱和脂肪酸（PUFA）（如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA））、环氧化酶-II（COX-2）和镇痛剂（如阿司匹林（ASA））之间的相互作用产生。令人惊奇的是，在适当的环境中仔细分离由各种成分组合产生的化合物，可以得到具有独特结构和生理特性的二羟基和三羟基 EPA 或 DHA 化合物。因此，本发明提供了许多新的有用的 EPA 或 DHA 的二羟基或三羟基治疗性衍生物（resolvins），这些衍生物可减轻、预防或消除炎症或 PMN 迁移等。本发明还提供了整个说明书中公开的化合物的使用方法、制备方法和用作药物的包装药品。
• Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
  申请人：Serhan N. Charles

  公开号：US20050261255A1

  公开（公告）日：2005-11-24

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

  本发明一般涉及新型分离治疗剂，称为 resolvins，由膳食中的ω-3 多不饱和脂肪酸（PUFA）如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA）、环氧化酶-II（COX-2）和镇痛剂如阿司匹林（ASA）之间的相互作用产生。令人惊奇的是，在适当的环境中仔细分离由各种成分组合产生的化合物，可以得到具有独特结构和生理特性的二羟基和三羟基 EPA 或 DHA 化合物。因此，本发明提供了许多新的有用的 EPA 或 DHA 的二羟基或三羟基治疗性衍生物（resolvins），这些衍生物可减轻、预防或消除炎症或 PMN 迁移等。本发明还提供了整个说明书中公开的化合物的使用方法、制备方法和用作药物的包装药品。